tiprankstipranks
Trending News
More News >
Purple Biotech Ltd. (IL:PPBT)
:PPBT
Israel Market

Purple Biotech (PPBT) AI Stock Analysis

Compare
0 Followers

Top Page

IL

Purple Biotech

(PPBT)

Rating:32Underperform
Price Target:
Purple Biotech struggles with significant financial challenges, including negative profitability and cash flow issues, heavily impacting its stock score. The technical analysis indicates a bearish trend, with some potential for a rebound given oversold conditions. Valuation remains unattractive due to negative earnings, further contributing to a low overall score.

Purple Biotech (PPBT) vs. iShares MSCI Israel ETF (EIS)

Purple Biotech Business Overview & Revenue Model

Company DescriptionPurple Biotech Ltd. (NASDAQ: PPBT) is a clinical-stage pharmaceutical company focused on developing innovative therapies that target cancer and other chronic diseases. The company specializes in oncology and immunology, leveraging its proprietary drug discovery platforms to advance a pipeline of novel drug candidates. Purple Biotech aims to address unmet medical needs through its research and development efforts, with a commitment to improving patient outcomes and enhancing the quality of life for individuals battling severe illnesses.
How the Company Makes MoneyPurple Biotech generates revenue primarily through partnerships, licensing agreements, and collaborations with other pharmaceutical companies. These agreements often involve upfront payments, milestone payments based on the achievement of specific development or regulatory milestones, and royalties on sales if the partnered products reach the market. Additionally, the company may receive research grants and funding from governmental and non-governmental organizations to support its R&D activities. Revenue streams are also bolstered by strategic alliances that facilitate the advancement and commercialization of its drug candidates, thereby expanding its market reach and enhancing potential returns on investment.

Purple Biotech Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.00195.80K0.000.001.00M
Gross Profit0.00-196.00-120.00-55.00999.94K
EBITDA-7.05M-22.23M-21.43M-17.38M-28.41M
Net Income-7.24M-19.88K-21.67M-18.38M-28.00M
Balance Sheet
Total Assets37.04M44.30M54.62M70.20M83.80M
Cash, Cash Equivalents and Short-Term Investments8.52M15.41M32.11M47.20M57.80M
Total Debt183.00K351.00K515.00K749.00K895.00K
Total Liabilities4.13M10.01M7.52M5.09M4.05M
Stockholders Equity32.86M34.21M46.91M64.83M79.39M
Cash Flow
Free Cash Flow-14.37M-19.93M-16.96M-15.19M-12.25M
Operating Cash Flow-14.37M-19.93M-16.73M-15.07M-12.09M
Investing Cash Flow509.00K13.88M19.91M13.41M-49.59M
Financing Cash Flow6.77M5.45M1.11M1.51M68.49M

Purple Biotech Technical Analysis

Technical Analysis Sentiment
Negative
Last Price4.30
Price Trends
50DMA
4.33
Negative
100DMA
4.80
Negative
200DMA
6.25
Negative
Market Momentum
MACD
-0.07
Positive
RSI
48.18
Neutral
STOCH
45.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:PPBT, the sentiment is Negative. The current price of 4.3 is above the 20-day moving average (MA) of 4.25, below the 50-day MA of 4.33, and below the 200-day MA of 6.25, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 48.18 is Neutral, neither overbought nor oversold. The STOCH value of 45.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:PPBT.

Purple Biotech Risk Analysis

Purple Biotech disclosed 74 risk factors in its most recent earnings report. Purple Biotech reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Purple Biotech Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$835.64M55.417.41%25.65%
56
Neutral
65.61B
2.44%-197.12%
52
Neutral
$7.50B0.31-61.87%2.27%17.10%1.59%
42
Neutral
47.80M
32
Underperform
23.85M
71.51%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IL:PPBT
Purple Biotech
4.20
-12.00
-74.07%
IL:BWAY
Brainsway
2,211.00
1,117.00
102.10%
IL:TEVA
Teva
5,721.00
-399.00
-6.52%
IL:CANF
Can Fite Bio
1.20
-1.90
-61.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 29, 2025